摘要
目的:探讨非小细胞肺癌(NSCLC)患者中耐药基因P-糖蛋白(P-gp),肺耐药相关蛋白(LRP)和谷胱苷肽-S转移酶(GST-π)的表达特点及对预后的影响.方法:用免疫组化方法检测168例非小细胞肺癌组织中的P-gp,LRP及GST-π表达情况并随访部分患者以研究其表达与预后的相关性.结果:在168例非小细胞肺癌患者中,P-gp,LRP和GST-π表达的阳性率分别为60.7%,64.03%和63.1%.P-gp和LRP与肿瘤组织类型有关,腺癌阳性率高于鳞癌(P<0.05);这3种耐药基因与病变大小相关,病变直径≥5 cm患者中,其阳性率高于直径<5 cm患者(P<0.05);有淋巴结转移患者P-gp和LRP的阳性表达率高于无淋巴结转移组(P<0.05);P-gp,LRP和GST-π表达为阴性患者2 a生存率高于阳性患者(P<0.05);三种耐药基因的表达与分化程度和年龄无关.结论:P-gp,LRP和GST-π的表达不仅与非小细胞肺癌的耐药情况有关,同时也可作为判断非小细胞肺癌患者预后的指标之一.耐药基因在非小细胞肺癌中的表达程度及特点不同,因而有必要对其进行联合检测以判断耐药及预后情况.
AIM： To investigate the expression characteristics of P-glycoprotein（ P-gp ）, lung resistance-related protein （ LRP ） and glutathiane S-transferase 7（GST-π） in non-small cell lung cancer （NSCLC） as well as their effects on the prognosis of patients. METHODS： The expressions of P-gp, LRP and GST-π in 168 patients with NSCLC were detected by immunohistochemistry and all patients were followed up. Some of them were followed up for more than 2 years to analyze the relationship between the expressions of P-gp, LRP and GST-π and the clinical prognosis of pa- tients. RF^UILTS： The positive rates of P-gp, LRP and GST-π expressions in NSCLC were 60.7%, 64.03% and 63.10%, respectively. The expressions of P-gp and LRP were associated with the types of histology. The positive rates of them in patients with squamous cell carcinoma were lower than those in ones with adenocarcinoma（P 〈0.05）. The expressions of the three drug resistant genes were associated with tumor size, and the positive rates of them in patients with tumor size more than 5 cm in diameter were higher than those in ones with tumor size less than 5 cm in diameter（ P 〈 0. 05 ）. The positive rates of P-gp and LRP were higher in patients with lymph node metastasis than those in ones without metastasis（P 〈0.05 ）. The three drug resistant gene expressions were also correlated with the 2-year survival rate （P 〈 0.05）. The expressions of the three drug resistant genes had no association with the sex and differentiations of histology.CONCLUSION： The expressions of P-gp, LRP and GST-π can be regarded as prognostic factors in NSCLC. Combined detection is necessary for evaluating the degree of drug resistance and prognosis of patients.
出处
《第四军医大学学报》
北大核心
2008年第15期1348-1351,共4页
Journal of the Fourth Military Medical University
基金
国家自然科学基金(30171052)
